FDA Panel Recommends Loosening Regulations on Six Peptide Treatments

A divided Food and Drug Administration (FDA) panel voted on July 24, 2026, to recommend loosening regulations on six peptide treatments, including BPC-157 for ulcerative colitis and Epitalon for insomnia. This decision, which follows a review by the Pharmacy Compounding Advisory Committee, could allow certain pharmacies to produce these peptides for prescription use, though some experts raised concerns about insufficient safety and efficacy data.